참고문헌
- Barnes FS, Greenebaum B : Handbook of Biological Effects of Electromagnetic Fields, ed 3. Boca Raton : CRC Press, 2006
- Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X : The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18 : 1129-1136, 2016 https://doi.org/10.1093/neuonc/now102
- Ciombor DM, Aaron RK : The role of electrical stimulation in bone repair. Foot Ankle Clin 10 : 579-593, vii, 2005 https://doi.org/10.1016/j.fcl.2005.06.006
- Clague DS, Wheeler EK : Dielectrophoretic manipulation of macromolecules: the electric field. Phys Rev E Stat Nonlin Soft Matter Phys 64(2 Pt 2) : 026605, 2001 https://doi.org/10.1103/PhysRevE.64.026605
- DeWitt JC, Mock A, Louis DN : The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol 30 : 643-649, 2017 https://doi.org/10.1097/WCO.0000000000000490
- Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, et al. : Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers (Basel) 11 : 174, 2019 https://doi.org/10.3390/cancers11020174
- Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, et al. : Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 5 : 18046, 2015 https://doi.org/10.1038/srep18046
- Gonzalez CF, Remcho VT : Harnessing dielectric forces for separations of cells, fine particles and macromolecules. J Chromatogr A 1079 : 59-68, 2005 https://doi.org/10.1016/j.chroma.2005.03.070
- Gutin PH, Wong ET : Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. Am Soc Clin Oncol Educ Book 32 : 126-131, 2012 https://doi.org/10.14694/EdBook_AM.2012.32.122
- Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr : Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J Med Econ 22 : 1006-1013, 2019 https://doi.org/10.1080/13696998.2019.1614933
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. : MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997-1003, 2005 https://doi.org/10.1056/NEJMoa043331
- Hondroulis E, Melnick SJ, Zhang X, Wu ZZ, Li CZ : Electrical field manipulation of cancer cell behavior monitored by whole cell biosensing device. Biomed Microdevices 15 : 657-663, 2013 https://doi.org/10.1007/s10544-013-9788-2
- Jo Y, Kim EH, Sai S, Kim JS, Cho JM, Kim H, et al. : Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy. Int J Mol Sci 19 : 3684, 2018 https://doi.org/10.3390/ijms19113684
- Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, et al. : Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. Oncogene 38 : 6630-6646, 2019 https://doi.org/10.1038/s41388-019-0882-7
- Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. : Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 104 : 10152-10157, 2007 https://doi.org/10.1073/pnas.0702916104
- Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. : Disruption of cancer cell replication by alternating electric fields. Cancer Res 64 : 3288-3295, 2004 https://doi.org/10.1158/0008-5472.CAN-04-0083
- Kirson ED, Schneiderman RS, Dbaly V, Tovarys F, Vymazal J, Itzhaki A, et al. : Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 9 : 1, 2009 https://doi.org/10.1186/1756-6649-9-1
- Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, et al. : Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study. Front Neurol 10 : 42, 2019 https://doi.org/10.3389/fneur.2019.00042
- Magouliotis DE, Asprodini EK, Svokos KA, Tasiopoulou VS, Svokos AA, Toms SA : Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. Acta Neurochir (Wien) 160 : 1167-1174, 2018 https://doi.org/10.1007/s00701-018-3536-6
- Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. : CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 Suppl 2 : ii1-ii56, 2013
- Salzberg M, Kirson E, Palti Y, Rochlitz C : A pilot study with very lowintensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie 31 : 362-365, 2008 https://doi.org/10.1159/000137713
- Silginer M, Weller M, Stupp R, Roth P : Biological activity of tumortreating fields in preclinical glioma models. Cell Death Dis 8 : e2753, 2017 https://doi.org/10.1038/cddis.2017.171
- Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. : Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318 : 2306-2316, 2017 https://doi.org/10.1001/jama.2017.18718
- Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. : Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314 : 2535-2543, 2015 https://doi.org/10.1001/jama.2015.16669
- Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group : High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5 : v190-v193, 2010 https://doi.org/10.1093/annonc/mdq187
- Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. : NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48 : 2192-2202, 2012 https://doi.org/10.1016/j.ejca.2012.04.011
- Swanson KD, Lok E, Wong ET : An overview of alternating electric fields therapy (NovoTTF Therapy) for the treatment of malignant glioma. Curr Neurol Neurosci Rep 16 : 8, 2016 https://doi.org/10.1007/s11910-015-0606-5
- Tuszynski JA, Wenger C, Friesen DE, Preto J : An overview of sub-cellular mechanisms involved in the action of TTFields. Int J Environ Res Public Health 13 : 1128, 2016 https://doi.org/10.3390/ijerph13111128
- van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. : Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 : 2715-2722, 2006 https://doi.org/10.1200/JCO.2005.04.6078
- Wong ET, Lok E, Swanson KD : Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Cancer Med 4 : 383-391, 2015 https://doi.org/10.1002/cam4.421
피인용 문헌
- The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway vol.12, 2020, https://doi.org/10.3389/fphar.2021.749242
- Tumor Treating Fields : Additional Mechanisms and Additional Applications vol.64, pp.3, 2020, https://doi.org/10.3340/jkns.2020.0188
- Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates vol.168, 2020, https://doi.org/10.1016/j.critrevonc.2021.103535
- Mechanisms involved in the anti-tumor effects of Toosendanin in glioma cells vol.21, pp.1, 2020, https://doi.org/10.1186/s12935-021-02186-2